6 research outputs found

    Redshift evolution of the underlying type Ia supernova stretch distribution

    No full text
    The detailed nature of type Ia supernovae (SNe Ia) remains uncertain, and as survey statistics increase, the question of astrophysical systematic uncertainties arises, notably that of the evolution of SN Ia populations. We study the dependence on redshift of the SN Ia SALT2.4 light-curve stretch, which is a purely intrinsic SN property, to probe its potential redshift drift. The SN stretch has been shown to be strongly correlated with the SN environment, notably with stellar age tracers. We modeled the underlying stretch distribution as a function of redshift, using the evolution of the fraction of young and old SNe Ia as predicted using the SNfactory dataset, and assuming a constant underlying stretch distribution for each age population consisting of Gaussian mixtures. We tested our prediction against published samples that were cut to have marginal magnitude selection effects, so that any observed change is indeed astrophysical and not observational in origin. In this first study, there are indications that the underlying SN Ia stretch distribution evolves as a function of redshift, and that the age drifting model is a better description of the data than any time-constant model, including the sample-based asymmetric distributions that are often used to correct Malmquist bias at a significance higher than 5σ. The favored underlying stretch model is a bimodal one, composed of a high-stretch mode shared by both young and old environments, and a low-stretch mode that is exclusive to old environments. The precise effect of the redshift evolution of the intrinsic properties of a SN Ia population on cosmology remains to be studied. The astrophysical drift of the SN stretch distribution does affect current Malmquist bias corrections, however, and thereby the distances that are derived based on SN that are affected by observational selection effects. We highlight that this bias will increase with surveys covering increasingly larger redshift ranges, which is particularly important for the Large Synoptic Survey Telescope

    Accuracy of environmental tracers and consequence for determining the Type Ia Supernovae magnitude step

    No full text
    International audienceType Ia Supernovae (SNe Ia) are standardizable candles that allow us to measure the recent expansion rate of the Universe. Due to uncertainties in progenitor physics, potential astrophysical dependencies may bias cosmological measurements if not properly accounted for. The dependency of the intrinsic luminosity of SNe Ia with their host-galaxy environment is often used to standardize SNe Ia luminosity and is commonly parameterized as a step function. This functional form implicitly assumes two-populations of SNe Ia. In the literature, multiple environmental indicators have been considered, finding different, sometimes incompatible, step function amplitudes. We compare these indicators in the context of a two-populations model, based on their ability to distinguish the two populations. We show that local Hα\alpha-based specific star formation rate (lsSFR) and global stellar mass are better tracers than, for instance, host galaxy morphology. We show that tracer accuracy can explain the discrepancy between the observed SNe Ia step amplitudes found in the literature. Using lsSFR or global mass to distinguish the two populations can explain all other observations, though lsSFR is favoured. As lsSFR is strongly connected to age, our results favour a prompt and delayed population model. In any case, there exists two populations that differ in standardized magnitude by at least 0.121±0.010mag0.121\pm0.010\,\mathrm{mag}

    Rivaroxaban with or without aspirin in stable cardiovascular disease

    No full text
    BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events
    corecore